{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:45:35Z","timestamp":1790765135886,"version":"4.1.0"},"reference-count":54,"publisher":"Wiley","issue":"S5","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The management of the disease of obesity has been transformed by incretin\u2010based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin\u2010based therapies in obesity management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review of amylin\u2010based therapies that were approved or remained in human clinical development for obesity as of 30 April 2026. PubMed\/MEDLINE, ClinicalTrials.gov, Google Scholar, company press releases, investor reports, and major congress abstracts were searched for relevant preclinical and clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Amylin, co\u2010secreted with insulin from pancreatic \u03b2\u2010cells, slows gastric emptying, suppresses glucagon secretion, and promotes meal termination through central mechanisms. Pramlintide, the first approved amylin analogue, established proof of concept but was limited by modest efficacy and frequent dosing. More recently, long\u2010acting amylin\u2010based therapies, including cagrilintide, eloralintide, petrelintide, MET\u2010233i, ABBV\u2010295, and AZD6234, as well as combination approaches such as cagrilintide with semaglutide and zenagamtide, have demonstrated clinically meaningful weight loss with generally favorable tolerability profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amylin\u2010based therapies represent a promising addition to the evolving treatment landscape of obesity. Their emerging efficacy as both standalone and combination therapies supports a multi pathway approach to addressing the biological complexity and heterogeneity of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71074","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:15:02Z","timestamp":1784096102000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early\u2010Phase Clinical Trials"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9460-1637","authenticated-orcid":false,"given":"Abdulhameed","family":"Alhazmi","sequence":"first","affiliation":[{"name":"Internal Medicine, Jazan University Hospital  Jazan Saudi Arabia"},{"name":"Diabetes Complications Research Centre, University College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[{"name":"Diabetes Complications Research Centre, University College Dublin  Dublin Ireland"},{"name":"Diabetes Research Centre, Ulster University  Coleraine UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230\u20108210.81938"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S31443"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14863"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaf036"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15478"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.70045"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.84"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255\u2010026\u201001465\u20104"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1096\/fba.2024\u201000151"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082207"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.7570\/jomes25085"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00324"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009\u20100546"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/db23\u20100571"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21\u201007\u201002413.2001"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706473105"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16628"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145721715607642"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.11.7.567"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16008"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010023\u201001429\u20108"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08\u20100029"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00297.2007"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006\u20100393"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105836"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589\u2010023\u201001393\u20104"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm9609"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075\u2010024\u201003361\u20102"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010025\u201006497\u20101"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13496"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401\u2010025\u201001635\u20102"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70439"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)02155\u20105"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102271"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70753"},{"key":"e_1_2_13_41_1","unstructured":"Roche Ltd. \u201cRoche Announces Positive Phase II Results for Petrelintide an Amylin Analog Developed for People Living with Overweight and Obesity [Press Release] \u201daccessed March 10 2026."},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01185"},{"key":"e_1_2_13_43_1","unstructured":"Metsera \u201cMetsera Announces Positive Phase 1 Data of First\u2010in\u2010Class Once\u2010Monthly Amylin Candidate MET\u2010233i Demonstrating Meaningful Weight Loss in Obesity [Press Release] \u201daccessed March 23 2026."},{"key":"e_1_2_13_44_1","volume-title":"Obesity","author":"Rauschecker M.","year":"2024"},{"key":"e_1_2_13_45_1","volume-title":"Diabetologia","author":"Hornigold D.","year":"2024"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M210"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.2006.2.3.203"},{"key":"e_1_2_13_48_1","unstructured":"Gubra \u201cGubra Announces Positive GUBamy Phase 1 Interim MAD Results [Press Release] \u201daccessed March 26 2026."},{"key":"e_1_2_13_49_1","unstructured":"Gubra \u201cAbbVie Reports Positive Phase 1 Multiple Ascending Dose Results for ABBV\u2010295 a Long\u2010Acting Amylin Analog [PRESS Release] \u201daccessed March 26 2026."},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1593134"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255\u2010024\u201001113\u20109"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010025\u201006637\u20107"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)01176\u20106"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)01185\u20107"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.139816"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71074","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71074","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:13:17Z","timestamp":1789744397000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":54,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/dom.71074"],"URL":"https:\/\/doi.org\/10.1111\/dom.71074","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"2026-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}